{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:52:48Z","timestamp":1781020368521,"version":"3.54.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2161,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1111\/j.1365-2133.2009.09260.x","type":"journal-article","created":{"date-parts":[[2009,5,25]],"date-time":"2009-05-25T15:58:51Z","timestamp":1243267131000},"page":"897-903","source":"Crossref","is-referenced-by-count":44,"title":["Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial"],"prefix":"10.1093","volume":"161","author":[{"given":"K.","family":"Gebauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shumack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.S.J.","family":"Cowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2133.1994.tb08544.x","article-title":"Epidemiology of solar keratoses","volume":"131","author":"Frost","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1085-5629(99)80003-0","article-title":"Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses","volume":"18","author":"Yantsos","year":"1999","journal-title":"Semin Cutan Med Surg"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB3","first-page":"6","article-title":"Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues","volume":"18","author":"Quatresooz","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(88)91658-3","article-title":"Malignant transformation of solar keratoses to squamous cell carcinoma","volume":"i","author":"Marks","year":"1988","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2000.103339","article-title":"The risk of progression to invasive disease","volume":"42","author":"Glogau","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB6","first-page":"1099","article-title":"The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma","volume":"33","author":"Fuchs","year":"2007","journal-title":"Dermatol Surg"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB7","first-page":"599","article-title":"Guideline Subcommittee of the European Dermatology Forum. Guidelines for the management of actinic keratoses","volume":"16","author":"Stockfleth","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0190-9622(95)90191-4","article-title":"Guidelines of care for actinic keratoses","volume":"32","author":"Drake","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2133.2006.07692.x","article-title":"Guidelines for the management of actinic keratoses","volume":"156","author":"de","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/09546630600765081","article-title":"Predictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey study","volume":"17","author":"Balkrishnan","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB11","first-page":"1","article-title":"Development of a treatment algorithm for actinic keratoses: a European Consensus","volume":"18","author":"Stockfleth","year":"2008","journal-title":"Eur J Dermatol"},{"issue":"Suppl. 4","key":"10.1111\/j.1365-2133.2009.09260.x-BIB12","first-page":"s36","article-title":"Mechanism of action and other potential roles of an immune response modifier","volume":"79","author":"Gaspari","year":"2007","journal-title":"Cutis"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0192-0561(98)00068-X","article-title":"Imiquimod applied topically: a novel immune response modifier and new class of drug","volume":"21","author":"Miller","year":"1999","journal-title":"Int J Immunopharmacol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archderm.134.1.25","article-title":"Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human papillomavirus","volume":"134","author":"Edwards","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0166-3542(99)00033-9","article-title":"Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%","volume":"43","author":"Arany","year":"1999","journal-title":"Antiviral Res"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB16","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1016\/S0041-1345(98)00806-9","article-title":"Posttransplantation skin cancer: scope of the problem, management, and role for systemic retinoid chemoprevention","volume":"30","author":"DiGiovanna","year":"1998","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB17","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1046\/j.1365-2133.2001.04197.x","article-title":"Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases","volume":"244","author":"Stockfleth","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00007435-200104000-00007","article-title":"Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day","volume":"28","author":"Fife","year":"2001","journal-title":"Sex Transm Dis"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB19","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0190-9622(99)70261-6","article-title":"Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream","volume":"41","author":"Beutner","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB20","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology","volume":"51","author":"Szeimies","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB22","unstructured":"22Aldara\u00ae (imiquimod cream, 5%) prescribing information. Bristol, TN: Graceway Pharmaceuticals, April 2007."},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB23","unstructured":"23Aldara\u00ae (imiquimod cream, 5%) consumer medicine information. Thornleigh, NSW: iNova Pharmaceuticals (Aust) Pty Ltd, December 2007."},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1067\/mjd.2002.126257","article-title":"Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial","volume":"47","author":"Salasche","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1046\/j.1440-0960.2003.00003.x","article-title":"Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial","volume":"44","author":"Chen","year":"2003","journal-title":"Australas J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","article-title":"Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3\u2003days per week in one or two courses of treatment for actinic keratoses on the head","volume":"57","author":"Jorizzo","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2133.2007.07942.x","article-title":"Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head","volume":"157","author":"Alomar","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09260.x-BIB28","unstructured":"28Aldara\u00ae (imiquimod cream, 5%) summary of product characteristics. Solna, Sweden: Meda AB, September 2008."}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2009.09260.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2009.09260.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:45:42Z","timestamp":1676382342000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/161\/4\/897\/6642159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09260.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}